

Sixuan Qian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7683566/publications.pdf>

Version: 2024-02-01

17
papers

350
citations

933447

10
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

540
citing authors

#	ARTICLE	IF	CITATIONS
1	The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2018, 66, 1-7.	0.8	86
2	Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 6448-6458.	1.8	54
3	TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2016, 9, 128.	17.0	36
4	Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 371-377.	1.3	32
5	Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses. <i>PLoS ONE</i> , 2010, 5, e13186.	2.5	27
6	Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigenâ€“Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 830-835.	2.0	22
7	Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2570-2579.	1.3	18
8	An Integrated Regulatory Network Based on Comprehensive Analysis of mRNA Expression, Gene Methylation and Expression of Long Non-coding RNAs (lncRNAs) in Myelodysplastic Syndromes. <i>Frontiers in Oncology</i> , 2019, 9, 200.	2.8	15
9	Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-15.	4.0	11
10	The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia. <i>Journal of Biomedical Research</i> , 2016, 30, 525.	1.6	10
11	Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia. <i>BMC Cancer</i> , 2018, 18, 1269.	2.6	9
12	Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia. <i>Hematology</i> , 2021, 26, 111-122.	1.5	9
13	The single nucleotide polymorphism and haplotype analysis of MDR1 in Chinese diffuse large B cell lymphoma patients. <i>Biomedicine and Pharmacotherapy</i> , 2015, 73, 24-28.	5.6	8
14	Co-occurrence of <i>KIT</i> and <i>NRAS</i> mutations defines an adverse prognostic core-binding factor acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2428-2437.	1.3	6
15	MDR1 polymorphisms affect the outcome of Chinese multiple myeloma patients. <i>Biomedicine and Pharmacotherapy</i> , 2017, 95, 743-748.	5.6	4
16	The combination therapy of imatinib and dasatinib achieves longterm molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia. <i>Journal of Biomedical Research</i> , 2014, 30, .	1.6	1
17	Functional Evaluation of KEL as an Oncogenic Gene in the Progression of Acute Erythroleukemia. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-13.	4.0	0